JP2024542633A - がん治療用cdk4阻害剤 - Google Patents
がん治療用cdk4阻害剤 Download PDFInfo
- Publication number
- JP2024542633A JP2024542633A JP2024532158A JP2024532158A JP2024542633A JP 2024542633 A JP2024542633 A JP 2024542633A JP 2024532158 A JP2024532158 A JP 2024532158A JP 2024532158 A JP2024532158 A JP 2024532158A JP 2024542633 A JP2024542633 A JP 2024542633A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- bid
- therapeutically effective
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285320P | 2021-12-02 | 2021-12-02 | |
| US63/285,320 | 2021-12-02 | ||
| US202263382346P | 2022-11-04 | 2022-11-04 | |
| US63/382,346 | 2022-11-04 | ||
| US202263383969P | 2022-11-16 | 2022-11-16 | |
| US63/383,969 | 2022-11-16 | ||
| PCT/IB2022/061525 WO2023100070A1 (en) | 2021-12-02 | 2022-11-29 | Cdk4 inhibitor for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542633A true JP2024542633A (ja) | 2024-11-15 |
| JP2024542633A5 JP2024542633A5 (cg-RX-API-DMAC7.html) | 2025-11-19 |
Family
ID=84440018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532158A Pending JP2024542633A (ja) | 2021-12-02 | 2022-11-29 | がん治療用cdk4阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041298A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4440576A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024542633A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240112931A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022400308B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3240993A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312650A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024006678A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI922768B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023100070A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| KR20250164842A (ko) | 2023-03-30 | 2025-11-25 | 화이자 인코포레이티드 | Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법 |
| EP4719405A1 (en) | 2023-06-02 | 2026-04-08 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| WO2026133192A1 (en) * | 2024-12-20 | 2026-06-25 | Pfizer Inc. | Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4772247A2 (en) * | 2013-08-14 | 2026-07-08 | Novartis AG | Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer |
| CN118286225A (zh) | 2018-04-26 | 2024-07-05 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
| WO2020157709A1 (en) * | 2019-02-01 | 2020-08-06 | Pfizer Inc. | Combination of a cdk inhibitor and a pim inhibitor |
| PT4181920T (pt) * | 2020-07-15 | 2025-11-04 | Ctxt Pty Ltd | Inibidor de kat6 e combinações para o tratamento do cancro da mama |
| CN116322693A (zh) * | 2020-08-13 | 2023-06-23 | 辉瑞公司 | 组合疗法 |
| MX2023003054A (es) * | 2020-09-15 | 2023-04-05 | Pfizer | Formas solidas de un inhibidor de cdk4. |
| EP4288057A4 (en) * | 2021-02-05 | 2025-03-12 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
-
2022
- 2022-11-29 AU AU2022400308A patent/AU2022400308B2/en active Active
- 2022-11-29 CA CA3240993A patent/CA3240993A1/en active Pending
- 2022-11-29 MX MX2024006678A patent/MX2024006678A/es unknown
- 2022-11-29 US US18/714,642 patent/US20250041298A1/en active Pending
- 2022-11-29 KR KR1020247021924A patent/KR20240112931A/ko active Pending
- 2022-11-29 WO PCT/IB2022/061525 patent/WO2023100070A1/en not_active Ceased
- 2022-11-29 EP EP22818896.7A patent/EP4440576A1/en active Pending
- 2022-11-29 JP JP2024532158A patent/JP2024542633A/ja active Pending
- 2022-11-29 IL IL312650A patent/IL312650A/en unknown
- 2022-12-01 TW TW111146137A patent/TWI922768B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024006678A (es) | 2024-06-19 |
| IL312650A (en) | 2024-07-01 |
| AU2022400308B2 (en) | 2026-02-12 |
| KR20240112931A (ko) | 2024-07-19 |
| EP4440576A1 (en) | 2024-10-09 |
| TWI922768B (zh) | 2026-04-21 |
| AU2022400308A1 (en) | 2024-05-16 |
| CA3240993A1 (en) | 2023-06-08 |
| TW202329970A (zh) | 2023-08-01 |
| WO2023100070A1 (en) | 2023-06-08 |
| US20250041298A1 (en) | 2025-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022400308B2 (en) | Cdk4 inhibitor for the treatment of cancer | |
| CN108024541B (zh) | 用于治疗癌症的方法 | |
| JP2024001009A (ja) | Pi3k阻害剤であるgdc-0077による癌の治療方法 | |
| JP2022504388A (ja) | Pi3kアルファ阻害剤およびメトホルミンを用いたがんの処置方法 | |
| EP4322941A1 (en) | Combination comprising ribociclib and amcenestrant | |
| JP7667132B2 (ja) | Atp競合性akt阻害剤、cdk4/6阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 | |
| EP4247363A1 (en) | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| AU2021227007A1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| US20250127759A1 (en) | Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer | |
| EP4301356A1 (en) | Treatment of breast cancer with amcenestrant and palbociclib | |
| AU2017245302B2 (en) | Pharmaceutical combinations | |
| CN118338901A (zh) | 用于治疗癌症的cdk4抑制剂 | |
| CN113509475A (zh) | Bcl-2/bcl-xl抑制剂的组合及相关用途 | |
| RU2854294C2 (ru) | Ингибитор cdk4 для лечения рака | |
| KR20210121188A (ko) | 아나스트로졸과 조합된 cdk4/6 억제제를 함유하는 조성물의 종양 질환 치료용 약제의 제조에서의 용도 | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| Kim et al. | A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer | |
| HK40110657A (en) | Cdk4 inhibitor for the treatment of cancer | |
| WO2024246824A1 (en) | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer | |
| AU2024269592A1 (en) | Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer | |
| AU2019255410B2 (en) | Nazartinib for use in the treatment of CNS metastasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251111 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251111 |